Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Leukemia × ME-401 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Leukemia 1

Interventions

Cyclophosphamide 159 Cytarabine 98 fludarabine phosphate 88 Methotrexate 83 Busulfan 76 Filgrastim 69 Rituximab 68 Peripheral Blood Stem Cell Transplantation 56 Etoposide 53 Radiotherapy 50 Cyclosporine 50 Antilymphocyte Serum 49 fludarabine 47 Mycophenolic Acid 47 Tacrolimus 44 Vincristine 41 Whole-Body Irradiation 40 Melphalan 38 Dexamethasone 34 Methylprednisolone 31 Imatinib Mesylate 31 Granulocyte Colony-Stimulating Factor 30 Daunorubicin 29 Alemtuzumab 29 sargramostim 27 Mercaptopurine 25 Azacitidine 24 Idarubicin 23 Prednisone 22 Doxorubicin 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05209308 2023-03-16

CORAL

MEI Pharma, Inc.

Phase 2 Withdrawn

Other hematologic neoplasm

Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡